Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
Proceeds from amended agreement, combined with finances raised from recent public stock offering and current financial resources, significantly extend Minerva cash runway
Combined proceeds are expected to support anticipated data readouts from five planned clinical trials with three product candidates
WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the European Commission has approved an amendment to its co-development and license agreement with Janssen Pharmaceutica NV (Janssen) related to MIN-202 (JNJ 42827922), a selective orexin-2 receptor antagonist, and the related repurchase of all Minerva shares owned by Johnson & Johnson Innovation - JJDC, Inc. (an affiliate of Janssen).
The effectiveness of this agreement, entered into in June 2017, was contingent upon approval of its terms by the European Commission and upon the closing of the acquisition of Actelion Ltd. by affiliates of Janssen. Each of these conditions has now been met, and the amendment is expected to take effect on August 29, 2017.
Under the amended agreement, Minerva gains global strategic control of the development of MIN-202 to treat insomnia, and Janssen foregoes its right to royalties on MIN-202 insomnia sales in Minerva territories. Minerva retains its rights to MIN-202 as adjunctive therapy for major depressive disorder (MDD), which include an exclusive license in the European Union, Switzerland, Liechtenstein, Iceland and Norway, with royalties payable by Minerva to Janssen, and royalties on sales payable by Janssen to Minerva elsewhere worldwide.
Payments to Minerva by Janssen under this new agreement include an upfront payment of $30 million, $20 million at the start of a Phase 3 insomnia trial for MIN-202 and $20 million when 50% of the patients are enrolled in this trial. Janssen has waived the remaining payments due from Minerva for Phase 2 development of MIN-202, which total approximately $13 million. Minerva has assumed all financial responsibility for Phase 3 development costs for MIN-202 in insomnia. All Minerva stock previously owned by Johnson & Johnson Innovation - JJDC, Inc., totaling approximately 3.9 million shares and representing approximately 9% of total Minerva shares outstanding, will be repurchased by Minerva at par value of $.0001 per share or approximately $389 in total.
As previously announced, Minerva's cash, cash equivalents and marketable securities as of June 30, 2017 were approximately $77.6 million. The Company completed a public offering on July 5, 2017 that resulted in net proceeds of approximately $41.5 million. Combined with the $30 million upfront payment and the waiving of $13 million in payments for Phase 2 development of MIN-202 under the amended agreement with Janssen, these total proceeds and savings are expected to support anticipated data readouts from five clinical trials projected to take place by the end of 2019. These include the Company's planned pivotal Phase 3 trial with MIN-101 in schizophrenia, three Phase 2b trials with MIN-202 in insomnia and MDD and a Phase 2b trial with MIN-117 in MDD. Additional clinical activity planned during that period includes a Phase 1 trial with MIN-301, which is in pre-clinical development.
About MIN-202 (JNJ 42827922)
MIN-202 is a selective orexin 2 receptor antagonist under development for the treatment of insomnia and as adjunctive therapy for MDD. In the brain, the orexin system is involved in the control of several key functions, including metabolism and wakefulness. MIN-202 seeks to inhibit the activity of the neurons that promote wakefulness by selectively blocking the orexin 2 receptor. Rather than making an individual sleepier, blocking the orexin 2 receptor reduces the level of the neurotransmitters that signal the brain to maintain vigilance and wakefulness.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to: the timing and results of future clinical milestones with MIN-101, MIN-202, MIN-117 and MIN-301; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our agreements with Janssen related to MIN-202; our ability to successfully develop and commercialize MIN-101, MIN-202, MIN-117 and MIN-301; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation: whether MIN-101, MIN-202, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of MIN-101, MIN-202, MIN-117 and MIN-301, if any, will be consistent with the results of past clinical trials; whether MIN-101, MIN-202, MIN-117 and MIN-301 will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission on August 3, 2017. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
NTT Security Launches Security Services for Industrial Control Systems20.9.2017 10:00 | Pressmeddelande
Cyber-defense for critical infrastructure including factories, plants, utilities & hospitals TOKYO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- NTT Security Corporation (Head Office: Chiyoda-Ku, Tokyo; CEO: Jun Sawada), the specialized security company of NTT Group, has launched "IT/OT Integrated Security Services". The new services will be taken to market globally through the NTT Group companies, Dimension Data, NTT Communications and NTT DATA, forming part of its suite of integrated services to enable successful digital transformation initiatives for its clients. Companies are increasingly working towards IT/OT (Operational Technology) alignment. OT systems, when connected to the internet, streamline business operations by advanced supply chain management, realization of mass customization and improvement of customer experience as well as find new intelligence employing IoT (the Internet of Things) and Big Data analytics. As a result, IT/OT convergence is ex
NTT Security lanserar säkerhetstjänster för industriella styrsystem20.9.2017 10:00 | Pressmeddelande
Cyberförsvar för kritisk infrastruktur, bland annat fabriker, anläggningar, försörjningssystem och sjukhus STOCKHOLM, 20 september 2017 (GLOBE NEWSWIRE) -- NTT Security Corporation, (huvudkontor: Chiyoda-Ku, Tokyo; CEO: Jun Sawada) det specialiserade säkerhetsföretaget inom NTT Group, lanserar IT/OT-integrerade säkerhetstjänster. De nya tjänsterna kommer att lanseras på den globala marknaden genom företag som ingår i NTT Group, nämligen Dimension Data, NTT Communications och NTT DATA. De kommer att ingå i ett erbjudande med integrerade tjänster som möjliggör en framgångsrik digital omvandling för företagets kunder. Företag arbetar alltmer med att sammanlänka IT och OT-system (IT-system för processtyrning) som gör att företagsverksamheter kan ansluts till internet. Detta sker genom en avancerad hantering av leveranskedjan, realisering av masskundanpassning och en förbättrad kundupplevelse. De införskaffar även ny information och underrättelser genom tillämpning av IoT (sak
Zumio(TM) Now Available in Europe20.9.2017 08:00 | Pressmeddelande
Exclusive Partnership Agreement Signed with Eropartner Distribution Ottawa, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Zumio Inc. proudly announces it has partnered exclusively with Eropartner Distribution for distribution across all 28 EU member countries. Winner of the Best New Product at ADULTEX 2017, Zumio is the world's only clitoral stimulator based on the proven circular fingertip motion. Zumio's patented SpiroTIP(TM) and motor clutch drive system allows users to dynamically go from high speed and intensity down to a low speed and intensity, without having to touch a control, to instinctively and more naturally, adjust the stimulation to suit their needs. "Traditional vibrators generate excess energy and shake everything they touch often creating sensory overload and a numbing effect," said Steve Traplin, Chief Revenue Officer at Zumio. " Our non-vibrating technology makes Zumio more comfortable to hold and the small TIP and
Juniper Systems Limited Eyes German Market with InterGeo 2017 Exhibit, Opens New Office in Wels, Austria20.9.2017 04:16 | Pressmeddelande
BIRMINGHAM, United Kingdom, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Manufacturer of rugged handheld data collectors Juniper Systems Limited aims to expand its footprint in the German marketplace. Coinciding with the opening of its new office in Wels, Austria, the company will exhibit at the geometrics industry trade fair, InterGeo 2017, next week in Berlin, Germany. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ec8e4e2c-b277-48f9-bce9-4606d17454a5 The Wels location was recently opened to serve German-speaking partners and customers in Austria, Germany, and other Eastern European countries. Juniper Systems will showcase its ultra-rugged solutions for GIS, geomatics and geoinformation applications in Hall 1.1 on Stand C1.010 on 26 - 28 September at InterGeo. 'We're excited to be exhibiting at the InterGeo trade fair, which is now a regular date in our diary', commented Simon Bowe, general manager of Juni
CallidusCloud Unveils Game-Changing Augmented Intelligence Platform for Sales Performance, Execution and Learning Customers19.9.2017 22:35 | Pressmeddelande
Thunderbridge AI³ Combines the Power of Artificial Intelligence, Application Integration, and Human Insight to Provide Contextual Augmented Intelligence Recommendations throughout the Lead to Money suite DUBLIN, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, unveiled its newest platform, Thunderbridge Augmented Intelligence - or Thunderbridge AI³ - today at CallidusCloud Connections (C3) 2017, its annual user conference. The new solution is comprised of three elements: artificial intelligence, application integration, and human insight. The Thunderbridge Augmented Intelligence platform is a layer of software that applies machine learning techniques to the sales and learning processes to come up with recommended actions for increasing revenue, profit, and sales effectiveness. The role of human insight and behavior is key to Thunderbridge AI
Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference19.9.2017 22:05 | Pressmeddelande
GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference. Presentation details are as follows: Date: Tuesday, September 26, 2017 Time: 11:00 - 11:25 am ET Location: Track 5, Montmartre, Sofitel Hotel, New York City Live webcast: www.novavax.com, "Investors"/"Events" A replay of the presentation will also be accessible under the "Investors/Events" section of the Novavax website at novavax.com. About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional inf
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum